Use of prostaglandin F2 alpha in the treatment of unobserved estrus in lactating dairy cattle

A field trial was conducted to evaluate the use of prostaglandin F2 alpha (PGF2 alpha) (lutalyse)a in lactating dairy cattle with unobserved estrus in the presence of a functional corpus luteum (CL) and clinically normal reproductive tract. Seventy-three Holstein and 9 Jersey cows, weighing between 340.0 and 772.7 kg, were allotted to treatment and control groups. All treated cows were inseminated within 80 hours after treatment as assigned by this trial. Control cows were inseminated at the first observed estrus. Of the treated cows, 50% showed estrus within 80 hours after treatment. In this trial, 96% of the treated cows and 92% of the control cows were determined to have at least 1 functional CL on the day of treatment. For the treatment group and the control group, mean serum progesterone concentrations were 4.1 ng and 3.5 ng (P less than 0.2, by Student's t test), respectively, on day of treatment and were 0.4 ng and 5.0 ng (P less than 0.005, by Student' t test) on day 5 after treatment. Pregnancy rates were 57% for treated and 47% for control cows (P = 0.5, by X2). Days from treatment to first-observed estrus, treatment to first service, and treatment to conception were significantly reduced in the treatment group compared with these criteria for the control group (P less than 0.05, 0.005, and 0.01 respectively). It was concluded that induction of luteolysis with PGF2 alpha in lactating dairy cattle with unobserved estrus and a palpable functional CL will be an effective addition to reproductive health programs.     

Effects of standing estrus and supplemental estradiol on changes in uterine pH during a fixed-time artificial insemination protocol

Cows that exhibit estrus within 24 h of fixed-time AI have elevated concentrations of estradiol and greater pregnancy rates compared with cows not in estrus. Our objective was to determine whether estradiol, estrus, or both had an effect on uterine pH during a fixed-time AI protocol. Beef cows were treated with the CO-Synch protocol (100 mircog of GnRH on d -9; 25 mg of PGF(2alpha) on d -2; and 100 mircog of GnRH on d 0). One-half of the cows received an injection of estradiol cypionate (ECP; 1 mg) 12 h after PGF(2alpha). Cows detected in standing estrus within 24 h of the second GnRH injection were considered to be in standing estrus. Uterine pH was determined in all animals 12, 24, and 48 h after the PGF(2alpha) injection. For Exp. 1, pH was also determined 72 and 96 h after the PGF(2alpha) injection; in Exp. 2, pH was also determined at 54, 60, 66, 72, 78, 84, 90, and 96 h after the PGF(2alpha) injection or until ovulation. A treatment x time interaction (P < 0.01) influenced concentrations of estradiol. All cows had similar (P > 0.15) concentrations of estradiol at the time of ECP administration, but after ECP treatment all cows treated with ECP and control cows that exhibited estrus had greater (P < 0.01) concentrations of estradiol compared with nontreated cows that did not exhibit estrus. In all animals, estradiol diminished 48 h after the PGF(2alpha) (time of the second GnRH injection), but ECP-treated cows, regardless of estrus, had elevated (P < 0.02) concentrations of estradiol compared with control cows. There was a treatment x time interaction (P < 0.001) on uterine pH. All cows had similar uterine pH (P > 0.19) 24 h after the PGF(2alpha) injection. Control cows that did not exhibit estrus had a greater uterine pH compared with control cows that exhibited estrus (P < 0.01) and ECP cows that exhibited estrus (P = 0.05) 48 h after the PGF(2alpha) injection (7.0 +/- 0.1 vs. 6.7 +/- 0.1 and 6.8 +/- 0.1, respectively). Estradiol cypionate-treated cows not exhibiting estrus were intermediate (6.8 +/- 0.1; P > 0.05). All cows had similar uterine pH 72 h after the PGF(2alpha) injection through ovulation (P > 0.06). In summary, uterine pH was similar among all animals that exhibited estrus, regardless of treatment with ECP.     

Influence of an agonist of gonadotropin-releasing hormone (buserelin) on estrus synchronization and fertility in beef cows.

The objective of this experiment was to determine the effect of sequential treatment with buserelin (a GnRH agonist) and cloprostenol (a prostaglandin F2 alpha analog) on estrous response and fertility in beef cattle with different ovarian conditions. On d 0 (1st d of treatment), the control group (n = 52, 10 heifers and 42 cows) and the GnRH group (n = 48, 10 heifers and 38 cows) received 2 mL of saline or 2 mL of Receptal (8 micrograms of buserelin), respectively. On d 6, all cows that had not exhibited spontaneous estrus were given i.m. 500 micrograms of cloprostenol (PGF). Ultrasonography on d 0 and assays of progesterone in blood on d -11, 0, and 6 were used to identify follicular and luteal status of animals. Cattle were observed for estrus from d 0 to 10. Cows showing estrus were bred artificially 12 h after onset of estrus. Over the 10-d period, the number of cows detected in estrus and pregnancy and conception rates were identical for the two groups. However, between d 0 and 6, the proportion of cows exhibiting estrus was lower (P less than .01) in the GnRH group than in the control group. Between d 6 and 10, the synchronization rate and precision of estrus were greater (P less than .01) in the buserelin-treated group than in the control group. Conception rate and interval from PGF injection to onset of estrus were not different between the two treatment groups. Presence of a large (greater than 10 mm) follicle on d 0 enhanced synchronization rate and precision of estrus.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effect of a 10 day postpartum administration of a PGF2 alpha analog at different concentrations on the course of the puerperium and fertility in dairy cows

In this double-blind Study 72 dairy cows were treated with injections of Luprostiol (Reprodin). 32 cows served as control. Gynaecological examinations in 10-day intervals up to day 40 post partum and determination of progesterone levels in milk samples taken in 3-day intervals up to day 73 p. p. were performed. The administration of PGF2 alpha did not improve the early onset of ovarian activity in cows with uncomplicated or complicated delivery. Ovaries without detectable function up to day 73 p. p. only occurred in the placebo group, representing a significant (p < 0.05) difference to the control group. In cows after uncomplicated as well as in animals after complicated delivery involution of the uterus up to day 20 p. p. progressed faster in the verum group compared to the control group. Cervical diameters were highest in the placebo group up to day 20 p. p. Until day 40 p. p. the cervical diameters of the probands equaled those of the control animals. In contrary to cows after uncomplicated delivery the injection of PGF2 alpha after complicated parturition lead to a significant (p < 0.05) reduction of puerperal endometritis. Neither in cows with uncomplicated nor complicated delivery the administration of PGF2 alpha resulted in an improved conception rate. There were no significant positive effects on fertility parameters to be detected in general. Partial results observed were not dose dependent.     

Carprofen in veterinary medicine. II. Inhibitory effect on the release of PGF2 alpha in the early postpartum cow

Carprofen, a non-steroidal anti-inflammatory drug (NSAID) known to inhibit prostaglandin synthesis, was given intravenously in five cows at a daily dose of 0.7 mg/kg for five days beginning on day 1 postpartum. Blood samples were collected at various times over a period of six days following the first injection. At this dose, carprofen reached highest plasma values of about 45 micrograms/ml after the fifth injection and was well tolerated by all the cows. During the whole experimental period, mean plasma levels of 15-keto-13, 14-dihydro-prostaglandin F2 alpha, the primary metabolite of PGF2 alpha, were significantly (p less than 0.05) lower in treated than in control animals (28-47% vs 64-101% of pretreatment concentrations). The suppressive effect of carprofen on PGF2 alpha-production occurred immediately after its application and was maximal 3-6 h post injection on the first and on the fifth experimental day (60-80% and 40-85%, respectively). We conclude from our results that carprofen in a single dose of 0.7 mg/kg b.w. effectively suppresses PGF2 alpha-release in the postpartum cow. Whether this effect is beneficial in the treatment of uterine inflammatory processes remains to be determined.     

Effect of three programmes for the treatment of endometritis on the reproductive performance of a dairy herd

Three management programmes to improve the reproductive performance of a dairy herd were compared in a prospective controlled field study on one commercial farm. A total of 542 cows were examined for endometritis 22 to 28 days postpartum and assigned to one of three treatment groups: in group 1 the cows with signs of endometritis were treated with an intrauterine infusion of 100 ml of a 2 per cent polycondensated m-cresolsulphuric acid formaldehyde solution; in group 2 the cows with signs of endometritis were treated with an intrauterine infusion of 125 ml of a 20 per cent eucalyptus compositum solution; and in group 3 all the cows were injected intramuscularly with 0.75 mg of tiaprost, an analogue of prostaglandin F2alpha (PGF2alpha) at two-week intervals, starting on day 43, until they were inseminated. Thirty-four per cent of the cows showed signs of endometritis. In group 3, oestrus detection efficiency was significantly higher than in groups 1 and 2 (P<0.05), the interval to first service was shorter, and the cows had fewer days open than the cows in groups 1 and 2 (P<0.05). The results indicate that management programmes based on the strategic use of PGF2alpha are an effective alternative to traditional programmes based on rectal palpations and intrauterine infusions to control endometritis at a herd level.     

Inhibitory effects of CIDR-based ovulation-synchronization protocols on uterine PGF2alpha secretion at the following luteal phase in early postpartum non-cycling beef cows

We investigated whether CIDR-based ovulation-synchronization protocols inhibit secretion of prostaglandin (PG) F2alpha from the uterus in the following luteal phase in non-cycling beef cows. Ten early (a month) postpartum non-cycling Japanese Black beef cows were treated with (1) Ovsynch (GnRH analogue on Day 0, PGF2alpha analogue on Day 7, and GnRH analogue on Day 9; n=3), (2) Ovsynch+CIDR (Ovsynch protocol plus a CIDR for 7 days from Day 0; n=4), or (3) estradiol benzoate (EB) Ovsynch+CIDR (EB on Day 0 in lieu of the first GnRH treatment followed by the Ovsynch+CIDR protocol; n=3). An oxytocin challenge was administered on Day 24 to examine uterine PGF2alpha secretion. Plasma concentrations of 13,14-dihydro-15-keto- PGF2alpha were lower at 30-120 min after oxytocin administration in the Ovsynch+CIDR group and 75 min after administration in the EB Ovsynch+CIDR group than in the Ovsynch group (P<0.05). Plasma progesterone concentrations were higher from Days 1 to 7 in the Ovsynch+CIDR group and from Days 1 to 5 in the EB Ovsynch+CIDR group than in the Ovsynch group (P<0.05). The progesterone concentrations were higher on Days 27 and 29 in both CIDR-treated groups than in the Ovsynch group (P<0.05). In conclusion, in non-cycling beef cows, CIDR-based ovulation-synchronization protocols inhibit uterine PGF2alpha secretion in the following luteal phase and prevent premature luteolysis as is seen with the Ovsynch protocol.     

Effects of prostaglandin F2 alpha-analogue administration on luteal function, implantation of embryos and maintenance of pregnancy in bitches

The present experiment was carried out to clarify the effect of administration of the prostaglandin F2 alpha (PGF2 alpha)-analogue on the luteal function and the maintenance of pregnancy in bitches. Fifty-one bitches received a single inoculation of PGF2 alpha-analogue by intramuscular injection. The effect of this agent was observed by monitoring progesterone (P) levels and the state of the uterus by laparotomy, the occurrence of abortion, and the state of parturition. As a result, when bitches were administered with 100-400 micrograms at the beginning of the luteal phase, the decrease in the P level was temporary. In bitches inoculated with 100-800 micrograms of PGF2 alpha-analogue at the functional luteal stage, the P level began to decrease as early as on the following day after injection. In those treated with 100-200 micrograms of PGF2 alpha-analogue at 10-15 days of pregnancy, pregnancy was maintained in 3 of 5 bitches that had received the treatment at day 10, while in the remaining two, all embryos died after implantation. In those that had received the same treatment at day 15, only 2 of 7 maintained pregnancy. Pregnancy was interrupted in eight bitches treated with doses of 100-200 micrograms at days 25-45. In four bitches treated with doses of 100-200 micrograms at day 55, premature birth was induced after 30-44 hr. In conclusion, regression of the corpus luteum, abortion, and premature birth were induced in bitches treated with 100-200 micrograms at each stage, except the beginning of the luteal phase and of the pregnancy.     

Reproductive efficiency in grazing lactating dairy cows under a programmed reproductive management system

OBJECTIVE: To evaluate the effectiveness of a reproductive management program consisting of combinations of Ovsynch/TAI and prostaglandin (PG) F(2alpha) treatments in Holstein dairy cows under a pasture-based dairying system. DESIGN: Field trial. PROCEDURE: A total of 1177 cows in 8 commercial dairy farms were randomly allocated to control and treatment groups. Treatment group cows received one of two interventions depending upon the number of days postpartum (DPP) before the planned start of breeding. Cows more than 50 DPP by the planned start of breeding received the Ovsynch/TAI treatment, consisting of gonadotrophin releasing hormone (GnRH) - PGF(2alpha)- GnRH plus timed artificial insemination. Cows between 40 and 50 DPP received a PGF(2alpha) treatment followed by oestrus detection and, if the cow was not seen in oestrus, the cow received a second PGF(2alpha) 14 days later. Control cows were submitted to twice a day heat detection followed by artificial insemination. The experimental period was the start of the breeding season plus 21 days for cows over 50 DPP at the start of breeding, and was 40-61 DPP for cows that calved later and passed their voluntary waiting period after the start of the breeding season. RESULTS: Submission rate was higher for the treated group than for the control group (84.9% vs. 55.1%; P < 0.0001), as was the conception rate (51.0% vs. 46.1%; P < 0.03). Due to farm variations, pregnancy rate was similar in both groups (38.5% vs. 28.2%; P > 0.1). Within the treated group, conception rate and pregnancy rate of the cows inseminated after a PGF(2alpha) were higher than for timed artificial inseminated cows (51.4% vs. 32.6%; P < 0.001), and (37.8% vs. 32.6%; P < 0.001). CONCLUSION: A programmed reproductive management protocol may improve reproductive efficiency in dairy farms with seasonal breeding, by increasing submission and conception rates at the beginning of the breeding season and/or at the end of the voluntary waiting period. Fertility of cows bred after a PGF(2alpha) synchronised heat was greater than after an Ovsynch/TAI protocol.     

Hormonal interrelationships in postpartum suckled dairy cows.

Three cross-bred cows calved in March and April and were followed until day 62 after parturition. Each animal was suckled by 2 calves ad libitum. All calves were removed from the cows on day 55 after parturition. Blood was collected 3 times per day from the jugular vein by venipuncture. On 4 occasions after parturition--i.e. days 7-8, 21-22, 35-36 and 49-50, the cows were bled through a jugular venous catheter every 30 min during the 24 h. The plasma samples were analyzed for the content of 15-keto-13,14-dihydro-PGF2 alpha (main PGF2 alpha metabolite), LH, prolactin, cortisol and progesterone by radioimmunoassay methods. The concentration of PGF2 alpha increased from 280 to 730 pmol/l within the last 4 days before parturition. The highest geometric mean was 3106 pmol/l on the day of parturition. Thereafter a steady decrease of PGF2 alpha metabolite concentration was seen until day 21 when it reached plateau at 148 pmol/l. In all cows plasma LH concentrations increased significantly (P < 0.05) from about 1.6 micrograms/l on days 7-8 to 2.4 micrograms/l on days 21-22 post partum. The frequency of LH pulses showed no tendency to increase as the postpartum period progressed and averaged 6.5 pulses/24 h. Mean plasma LH concentrations increased from 2.1 micrograms/l 2 days before weaning to 3.2 micrograms/l 2 days after weaning (P < 0.05). LH peaks occurred less frequently in association with prolactin and cortisol peaks than in their absence. A partial positive correlation between PGF2 alpha metabolite and cortisol (r = 0.30) was found on days 7-8 post partum. Correlation between prolactin and cortisol on days 7-8 and 21-22 post partum was also positive (r = 0.20 and r = 0.27, respectively). There was a negative correlation between LH and cortisol on days 7-8 (r = -0.27) and days 49-50 (r = -0.21) post partum. The first and short progesterone increase observed after weaning was terminated in conjunction with PGF2 alpha metabolite peaks.     

Comparision of ovulation synchronization (OVSYNCH) with the selective induction of oestrus using PGF2alpha after rectal palpation in a dairy herd

The efficacy of a protocol for the synchronization of ovulation followed by timed Al (OVSYNCH) was compared with a reproductive management protocol based on induction of oestrus after rectal palpation using PGF2alpha on a commercial dairy farm in Brandenburg, Germany. Cows in the OVSYNCH group (n = 309) were treated between 62 and 68 days in milk (DIM) with 0.02 mg of buserelin (GnRH analogue) intramuscularly (i.m.). Seven days later 0.75 mg of tiaprost (PGF2alpha-analogue) were administered i.m. to regress the corpus luteum (C.I.). All cows received a second treatment with GnRH another 48 hrs later and were inseminated 16 to 20 hrs after the second GnRH-treatment (72 to 78 DIM). Cows in the PGF group (n = 302) were examined by rectal palpation between 69 and 75 DIM. Cows with a C.I. received 0.75 mg of tiaprost to induce oestrus. Cows were inseminated on observed oestrus. Cows not inseminated within 14 days after treatment were re-examined between 83 and 89 DIM. For both groups, the voluntary waiting period was set at 72 DIM. Service rate was higher (86.4 vs. 63.2 %, P < 0.05), days to first service (77 +/- 11 vs. 86 +/- 19 days, P < 0.001) and days open (102 +/- 34 vs. 109 +/- 35 days, P < 0.05) were shorter in the OVSYNCH group. First service conception rate (40.3 vs. 42.4 %), conception rate to all services (37.9 vs. 40.0 %) and the proportion of pregnant cows at 200 DIM were similar in the OVSYNCH evaluation for the total costs per pregnancy in 71 different cost scenarios showed only slight differences between the groups. Mean costs per pregnancy were euro 235.43 and euro 235.08 for the OVSYNCH and the PGF group, respectively. Quality of oestrus as assessed by the Al technician did not reveal a relationship to conception rate after OVSYNCH and timed Al. However, swelling, hyperaemia and a moist vestibulum were positively associated with conception rate.     

Efficacy of 1 alpha hydroxyvitamin D3 in the prevention of bovine parturient paresis

One hundred and seventeen Israeli-Friesian cows from herds with a milk fever incidence of more than 15 per cent were injected intramuscularly with either 350 micrograms 1 alpha hydroxyvitamin D3 (1 alpha OHD3) in propylene glycol or with the vehicle alone, close to calving. If parturition had not occurred within 72 hours a second injection was administered; parturition was induced two days after the second injection if necessary. There were 10 cases of milk fever among 57 control cows as opposed to two cases among the 60 animals treated with 1 alpha OHD3. In an attempt to prolong the effect of the drug, Israeli-Friesian cows were injected intramuscularly with 350 micrograms 1 alpha OHD3 in either 10 ml propylene glycol or arachis oil. 1 alpha OHD3 in arachis oil did not prolong the effect of the drug. 1 alpha OHD3 in propylene glycol increased plasma calcium concentrations more rapidly than when the drug was administered in oil. Additional cows of the same breed and age were injected intramuscularly with 350 micrograms 1 alpha OHD3 in propylene glycol. Five of the animals received a second dose four days, and five received a second dose five days after the first injection. Five animals served as uninjected controls. The plasma calcium levels of the injected cows were significantly higher (P less than 0.01) than those of the controls from the second until the 14th day after the first injection. Based on these results 451 Israeli-Friesian cows from herds with a milk fever incidence of more than 15 per cent were injected intramuscularly with 1 alpha OHD3 close to calving.(ABSTRACT TRUNCATED AT 250 WORDS)     

Retrospective analysis of the efficacy of different hormone treatments of cystic ovarian disease in cattle

Cystic ovarian disease in cows was treated either with a single intramuscular injection of 500 micrograms cloprostenol, a prostaglandin F2 alpha analogue, in 77 cases of luteal cysts or with 500 micrograms gonadorelin or 20 micrograms buserelin, gonadotrophin releasing hormone or its analogue (GnRH), in 116 cases of follicular cysts. Recovery was defined as the absence of cysts and the formation of a corpus luteum either with or without observed oestrus within 10 days after treatment with cloprostenol and 15 days after treatment with GnRH. Recovery occurred in 65 per cent and 52.6 per cent of cases, respectively, in average times of 4.9 and 19 days. Fifteen days after treatment with GnRH, 20 cows with luteinised cysts were treated with cloprostenol and 15 recovered in a mean of 20.4 days, while 10 which still had follicular cysts, were given GnRH and one recovered 31 days after the beginning of treatment. Another 27 cows, in which cysts became luteinised, were treated with cloprostenol seven days after treatment with GnRH to give quicker (average 11.5 days) but poor (48 per cent) recovery and with a higher rate (33 per cent) of recurrence of cysts. A progesterone releasing intrauterine device was used in 25 cases of cystic ovarian disease, some of which had been previously treated. Sixty-eight per cent recovered in an average of 15 days. The proportions of cows becoming pregnant to one to three inseminations after the different methods of treatment were similar (77 to 94 per cent).(ABSTRACT TRUNCATED AT 250 WORDS)     

Repeated oestrus synchronisation of beef cows with progesterone implants and the effects of a gonadotrophin-releasing hormone agonist at implant insertion

A group of 97 spring-calving beef cows were initially oestrus synchronised with controlled internal drug release (CIDR) intravaginal progesterone implants inserted for nine days and a prostaglandin injection on day 7. Approximately half the cows were given 10 microg buserelin when the implants were inserted, and they all received a single fixed-time artificial insemination (AI) 56 hours after the withdrawal of the implants. The overall pregnancy rate to the first synchronised AI was 55 per cent, the buserelin-treated cows having a pregnancy rate of 63 per cent compared with 47 per cent in the untreated cows (P>0.05). Sixteen days after the first synchronised AI all the cows were re-implanted with used CIDR implants which were removed five days later, and the cows received a second synchronised AI on days 23 to 24. Cows which received the second AI were implanted with new CIDR devices 16 days later and these were removed after five days and the non-pregnant cows received a third synchronised AI. The pregnancy rates to the second and third synchronised services were 74 per cent and 75 per cent, respectively.     

The use of bovine anti-PMSG serum in beef cattle after PMSG-superovulation.

Thirteen beef cows were superovulated using 4,000 i.u. of pregnant mare serum gonadotrophin (PMSG) on days 9 to 14 of the estrous cycle, followed by two injections of 500 micrograms prostaglandin F2 alpha analogue (PGF2 alpha) 48 and 55 hrs later. Seven of them were injected intramuscularly with bovine anti-PMSG serum 12 hrs after the first signs of estrus. The remaining 6 cows were served as controls and received no antiserum. Peripheral blood concentrations of progesterone (P) and estradiol-17 beta (E2) were compared in relation to the superovulatory responses. The injection of anti-PMSG serum did not significantly affect the numbers of the corpora lutea (CL), the anovulatory follicles and the transferable embryos at 7 to 8 days after superovulatory estrus, but increased the ratio of embryos classified as excellent or good quality. Although the plasma P concentration showed no significant differences between the anti-PMSG-treated and control cows, the plasma E2 concentration displayed a characteristic difference, suppressing the second E2 peak in the anti-PMSG-treated cows. It is concluded that the use of bovine anti-PMSG serum for PMSG/PGF2 alpha-treated cows at 12 hrs after the beginning of the estrus improves the quality of embryos recovered, probably due to inhibition of high estrogenic environment following ovulation.     

Comparison of Two Different Programmes of Ovulation Synchronization in the Treatment of Ovarian Cysts in Dairy Cows

It was the aim of this field study to evaluate two different protocols of ovulation synchronization for the treatment of ovarian cysts and their effect on reproductive performance in dairy cows. In addition, factors with a possible influence on treatment success and pregnancy outcome as well as costs per pregnancy were analysed. The study was performed with 130 German Holsteins with ovarian cysts diagnosed on days 55 to 60 postpartum. Cows belonging to group 1 (n = 65) received a modified ovsynch protocol [day 0: 0.15 mg cloprostenol (PGF) + 0.02 mg buserelin acetate (GnRH); day 14: PGF; day 16: GnRH]. Group 2 (n = 65) was treated with the conventional ovsynch protocol (day 0: GnRH; day 7: PGF; day 9: GnRH). Timed artificial insemination was performed 20 to 24 h later. Cows without ovarian cysts served as controls. Treatment success (disappearance of the ovarian cyst) after the first ovsynch cycle was higher in group 1 (66.2%) than in group 2 (23.1%, p < 0.05). Reproductive measures in group 1 were comparable with those of the control group and, compared with group 2, were conspicuously better (66.2%, 76.9%, 83.1%, 59.5% vs. 40.0%, 50.7%, 60.0%, 27.5% for cumulative pregnancy rate after treatment cycle 1 to 3 and second service conception rate, respectively, p < 0.05). Overconditioned cows and cows with larger ovarian cysts showed a diminished treatment and pregnancy success. In group 1, costs per pregnancy were only slightly higher than in the control group (group 1: €352.44, group 2: €484.59, control group: €333.77). In conclusion, our results suggest that ovsynch protocols can be used in the treatment of ovarian cysts. The modified ovsynch protocol led to a better cure rate as well as a better reproductive performance, and was economically beneficial compared with a conventional ovsynch protocol.     

Combined GnRH and PGF2α Application in Cows with Endometritis Puerperalis Treated with Antibiotics

The investigations were carried out on a total of 70 cows with puerperal endometritis. In addition to intrauterine antibiotic treatment, 30 experimental animals were administered 20 μg GnRH analogue, buserelin, between days 10 and 12 post‐partum followed by 500 μg PGF_2α analogue, cloprostenol, 10 days later. Forty control cows were treated only with intrauterine antibiotics. Blood samples for progesterone determination were collected from the tail vein twice weekly until day 70 post‐partum. The first rise in progesterone level above 3.18 nmol/l occurred significantly earlier in the experimental than in control cows (21.6 ± 9.2 versus 27.8 ± 12.3 days; p ≤ 0.05). The duration of the first cycle post‐partum was 15.0 ± 4.3 days in experimental and 19.7 ± 7.3 days in control animals (p ≤ 0.05). However, no significant differences were observed in the occurrence of first oestrus post‐partum. The involution of the uterus was improved after hormone treatment. At day 42 post‐partum, completion of uterine involution was found in 93.3% of hormone‐treated cows and in 82.5% of those treated with antibiotic only (p ≤ 0.05). Clinical recovery was 96.6% in the experimental and 82.5% in the control group (p ≤ 0.05). First service pregnancy rate was significantly better in hormone‐treated than control cows (51.7 versus 36.4%; p ≤ 0.05). Total pregnancy rate and insemination index values were not significantly improved following GnRH and PGF_2α treatment. The average service period was 89.8 ± 21.2 days in cows after hormone treatment, and 112.6 ± 24.5 days in control cows. The difference was statistically significant (p ≤ 0.05). These results indicate, that the sequential GnRH and PGF_2α application in cows with puerperal endometritis positively affected ovarian function and uterine involution, resulting in improved fertility performance.     

Synchronisation of oestrus and fertility in buffaloes using a prostaglandin analogue

Cloprostenol, a prostaglandin analogue, was administered intramuscularly to a total of 35 cycling buffalo cows and heifers in two doses, each of 0.5 mg, given 11 days apart. Out of five cows and 12 heifers subjected to observations after the second injection of cloprostenol (day 0), all except one heifer responded. Signs of oestrus were most marked on days 3 or 4. Eighteen treated heifers were kept with buffalo bulls for four days after the second injection while a control group of nine heifers was kept with bulls for 21 days. The first-service conception rate, diagnosed by rectal palpation at 60 days, was 33 1/3 per cent in both groups. Twelve treated heifers were artificially inseminated at 72 and 96 hours after the second injection of cloprostenol, using fresh semen diluted in egg yolk--citrate extender. The first service conception rate at 60 days was 30 per cent.     

Synchronization of ovulation (OVSYNCH) in high producing dairy cattle herds. Part II: Milk yield, diseases and cost-benefit-analysis

A method for synchronization of ovulation (OVSYNCH) was evaluated for its practical use in seven North German dairy cattle herds. The original procedure of PURSLEY et al. (1995) was applied, i. e. cows were treated with Gonadotropin Releasing Hormone (GnRH) at a random stage of the estrous cycle, followed by an injection of a prostaglandin F2alpha (PGF2alpha)-analog seven days later and another injection of GnRH two days after PGF2alpha. Cows were inseminated 24 h after the last injection by artificial insemination. Control animals were assigned by corresponding lactation number and month of lactation. Cows from the OVSYNCH group returned to the conventional reproductive management after the OVSYNCH treatment, which was the same management as that for the control group. The parameters of fertility and correlations between body condition score (BCS) as well as concentrations of serum progesterone and the success of OVSYNCH were presented in the first report. For the OVSYNCH group, the 100-day-duction during the time period from calving until a pregnancy was established differed markedly from healthy cows in a variety of parameters. Healthy cows had a greater FSC (65.22%) than sick cows (35.90%) (P < 0.05). Furthermore, mean days open were less in healthy cows than in sick cows (85.48 +/- 30.56 days vs 110.85 +/- 46.40 days) (P < 0.05). Cows showing a disease had a higher number of lactation (4.00 +/- 2.26 vs. 2.80 +/- 1.35; P < 0.01) and a decreased BCS (2.72 +/- 0.23 vs. 2.91 +/- 0.23; P < 0.05). Sick and healthy cows from the OVSYNCH group did not differ with regard to 100-day-milk-yield (milk kg, relative and absolute milk fat and protein content). The cost-benefit-analysis revealed higher total cost, and cost per pregnancy (16,408.07 euros and 278.10 euros, respectively) in the control group than in the OVSYNCH group (11,015.69 euros and 196.71 euros, respectively).     

Failure of an intramuscular injection of an analogue of gonadotrophin-releasing hormone 11 to 13 days after insemination to increase pregnancy rates in dairy cattle

At 11 to 13 d after insemination, 1028 dairy cows on 19 farms were given an intramuscular injection of 10 micrograms of the GnRH analogue buserelin. Their reproductive performance was compared to 1022 control cows receiving a placebo. The GnRH analogue-treated cows had fewer short interoestrous intervals compared to the control cows, but there were no significant differences in pregnancy rates to either the insemination preceding or following treatment, in calving to conception interval, or to percent pregnant by the end of mating. There were no differences between treatments in herds of high, average or low pregnancy rate, in 2-year-old cows or cows greater than 2-years-old and in cows calved 40 d or less, or greater than 40 d. The use of 10 micrograms of the GnRH analogue, buserelin, 11 to 13 d after insemination, cannot be recommended as a method of improving reproductive performance in dairy herds.